The aim of the Education Committee (EC) is to coordinate ESOT’s efforts to advance multidisciplinary education for transplant professionals at all career levels and to contribute to their professional development.
The Basic Science Committee promotes scientific issues and transplantation research within ESOT. An active basic science community and an efficient translation of innovation into the clinic are crucial for the future of transplantation medicine.
The European Transplant Allied Healthcare Professionals (ETAHP) reaches out to allied healthcare professionals throughout Europe in order to ensure the best care possible for all transplant patients, with the aim to optimize patient outcomes.
The Young Professionals in Transplantation (YPT) is the Network for Junior Transplant professionals of ESOT, representing all young transplant clinicians and scientists who are beginning a career in transplantation and organ donation.
The mission of ECTORS is to provide a forum for discussing and stimulating novel developments in the fields of cellular therapies in organ transplantation, organ regeneration and generation of new organs from stem cells and biomaterials.
ECTTA is the forum for experience exchange on treatment of patients with end-stage heart and lung failure. Our aim is to improve outcomes for the patients.
EDTCO aims to support health care professionals to provide clinically effective programmes on organ and tissue donation, procurement and transplantation.
EKITA is the Organ Expert Section of ESOT on kidney transplantation in Europe, providing a forum for kidney transplantation professionals to exchange scientific information and views aimed at providing the best service to European patients .
The European Liver and Intestine Transplant Association (ELITA), previously known as the European Liver Transplant Association (ELTA), is a section of ESOT. Its membership represents the expertise on liver and intestinal transplantation in Europe.
ELPAT is a European platform that brings continuity and progress in European research and dialogue on "Ethical, Legal and Psychosocial Aspects of organ Transplantation". ELPAT currently consists of over 160 experts from more than 25 European countries.
EPITA is established to provide a forum for those working in the field of pancreas and islet of Langerhans transplantation or any other alternative form of beta cell replacement in Europe, to exchange scientific information and views related primarily to providing the best service for patients in Europe requiring pancreas or islet transplantation.
VCA has opened a new era in the field of transplantation, reconstructive and restorative surgery. This Section brings together 10 representatives of major European teams at the forefront in this field.
Throughout her career Pr. Lefaucheur has been able to build a teamwork among peers with different needs and interests. She has co-founded the Paris Translational Research Center for Organ Transplantation, a network of more than 43 centres in France, Europe and the US, three times awarded with the PRO ESOT Stronger Together Awards, and more recently the Paris Institute for Transplantation & Organ Regeneration. She was awarded the 2023 Paul I. Terasaki Clinical Science Award, the “International Transplant Society New Key Opinion Leader Award” in 2010 and the “Prix de la Chancellerie des Universités de Paris” award in 2014. She is engaged in several national and international Scientific Societies, as Member of the Board of Trustees of the Banff Allograft Pathology Foundation, Member of STAR working group of ASHI and AST, Member of the Scientific Programme Committee of ESOT 2023, and Mentor for the ESOT Mentorship Programme.
She is principal investigator of national and international clinical trials dedicated to prophylaxis and treatment of rejection in kidney transplantation, including ongoing research funding most notably the EUTRAIN H2020 project and the KTD-Innov project for Precision Risk Stratification in Kidney Transplant patients.
Her research aims to develop a translational research model in organ transplantation based on a multidisciplinary approach which may connect immunological, histological, molecular and clinical knowledge. She has focused on the clinical relevance of HLA antibodies and their different mechanistic pathways leading to allograft antibody-mediated rejection, thereby addressing the heterogeneity of its phenotypic expression and eventually investigating new tailored potential therapies in transplant populations.
